Pacific Biosciences' Top-Line Q3 Results Hit by Lower Contract Revenue | GenomeWeb

This story has been updated to include management comments made during a conference call.

NEW YORK (GenomeWeb) – Pacific Biosciences reported after the close of the market on Thursday that its third quarter revenues dropped 33 percent compared to the prior-year period, due to a $10 million milestone payment from Roche in Q3 2014 that wasn’t repeated in the most recent quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.